Physician profile
Peter C Nalos
NPI 1609055078
$9,610.92
in general payments reported to CMS, 2019-2025
30 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,870 · 2020: $890 · 2021: $878 · 2022: $1,401 · 2023: $1,473 · 2024: $1,758 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,572.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,297.25 | 2019-2025 | Gallant, Aveir, Merlin@Home |
| Medtronic Vascular, INC. | $1,129.85 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $616.92 | 2021-2025 | Verquvo |
| Amgen INC. | $609.75 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $327.62 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $287.94 | 2021-2025 | Andexxa, Wainua, Farxiga |
| Cvrx, INC. | $220.46 | 2022-2023 | Barostim Neo System |
| Heartflow, INC. | $160.31 | 2025 | |
| Pfizer INC. | $149.28 | 2022-2025 | |
| Irhythm Technologies, INC. | $83.45 | 2022-2023 | Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.30 | 2021-2022 | |
| Scpharmaceuticals INC. | $69.26 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $62.36 | 2021-2025 | Amvuttra |
| Gilead Sciences, INC. | $56.93 | 2019 | |
| Akcea Therapeutics, INC. | $54.82 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $49.48 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $38.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.34 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.84 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $30.53 | 2024 | Optimizer |
| Kowa Pharmaceuticals America, INC. | $29.71 | 2019 | |
| Medtronic, INC. | $29.23 | 2025 | Symplicity G3 |
| Altathera Pharmaceuticals LLC | $28.53 | 2024 | Sotalol Hydrochloride |
| Esperion Therapeutics, INC. | $26.95 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $25.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.78 | 2023 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $22.82 | 2023 | Inpefa |
| Daiichi Sankyo INC. | $17.74 | 2023 | Injectafer |
| Amarin Pharma, INC. | $12.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nalos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.